文献类型：期刊文献

英文题名：A study of factors influencing access to MDT among patients with stage III to stage IV colorectal cancer: a national multicenter survey

作者：Wang, Xiao-Hui[1];Wang, Zu-Zhi[2];Xu, Hui-Fang[3,4];Liu, Hong-Wei[3,4];Wang, Dong-Ling[2];Feng, Chang-Yan[5];Zhang, Xi[6];Wang, Wen-Jun[7];Yu, Yan-Qin[8];Duan, Shuang-Xia[9];Shi, Ji-Hai[8];Zhao, Yu-Qian[10];Li, Ma[11];Liu, Yun-Yong[12];Huang, Juan-Xiu[13];Fan, Yan-Ping[14];Cao, Ji[15];Gu, Xiao-Fen[16];Li, Li[17];Lian, Xue-Mei[18];Du, Jing-Chang[19];Qiao, You-Lin[3,4]

第一作者：Wang, Xiao-Hui

通信作者：Qiao, YL[1];Qiao, YL[2]

机构：[1]Gansu Prov Canc Hosp, Lanzhou, Peoples R China;[2]Gansu Univ Chinese Med, Sch Publ Hlth, Lanzhou, Peoples R China;[3]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China;[4]Henan Canc Hosp, Henan Engn Res Ctr Canc Prevent & Control, Henan Int Joint Lab Canc Prevent, Zhengzhou, Peoples R China;[5]Chongqing Univ, Chongqing Key Lab Translat Res Canc Metastasis & I, Canc Hosp, Chongqing, Peoples R China;[6]Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Beijing Off Canc Prevent & Control, Minist Educ Beijing, Beijing, Peoples R China;[7]Jining Med Univ, Sch Nursing, Jining, Peoples R China;[8]Baotou Med Coll, Res Ctr Clin epidemiol, Dept Publ Hlth & Prevent Med, Baotou, Inner Mongolia, Peoples R China;[9]Xinxiang Cent Hosp, Xinxiang, Peoples R China;[10]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China;[11]Dalian Med Univ, Publ Hlth Sch, Dalian, Peoples R China;[12]China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Liaoning Off Canc Control & Res, Shenyang, Peoples R China;[13]Wuzhou Red Cross Hosp, Wuzhou, Peoples R China;[14]Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China;[15]Guangxi Med Univ, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China;[16]Xinjiang Med Univ, Affiliated Tumor Hosp, Urumqi, Xinjiang, Peoples R China;[17]Jinan Univ, Affiliated Hosp 1, Dept Clin Res, Guangzhou, Guangdong, Peoples R China;[18]Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China;[19]Chengdu Med Coll, Coll Publ Hlth, Chengdu, Peoples R China

第一机构：Gansu Prov Canc Hosp, Lanzhou, Peoples R China

通信机构：[1]corresponding author), Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China;[2]corresponding author), Henan Canc Hosp, Henan Engn Res Ctr Canc Prevent & Control, Henan Int Joint Lab Canc Prevent, Zhengzhou, Peoples R China.

年份：2026

卷号：16

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-105042260806);WOS:【SCI-EXPANDED(收录号:WOS:001778856400001)】；

基金：The author(s) declared that financial support was received for this work and/or its publication. This study is funded by Beijing Love Book Cancer Foundation and Merck Serono Co. (grant number). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

语种：英文

外文关键词：factors; MDT; quality of life; stage III to IV CRC; treatment modalities

摘要：Background and objective: The disease burden of colorectal cancer (CRC) in China is relatively heavy, and although the multidisciplinary treatment (MDT) model can improve efficacy and resource efficiency, there are inequalities in its accessibility. The aim of this study was to investigate the key factors affecting access to MDT among patients with stage III to stage IV CRC. Methods: A multi-stage stratified sampling method is adopted to conduct a cross-sectional survey of 4,589 stage III-IV colorectal cancer (CRC) patients across 19 hospitals nationwide. Results: Only 796 (17.3%) of the 4,589 patients with stage III-IV CRC included in this study participated in MDT, with more males (61.4%) than females (38.6%). Univariate analysis showed that:patients' location, medical visits to provincial-capital-city-hospitals and prefecture-level-city-hospitals, education background, number of medical institutions been visited, family income, patients' circumstance of disease, initial diagnosis stage, whether metastasis occurred at initial diagnosis, endoscopic interventional therapy, chemotherapy, targeted therapy, traditional Chinese medicine(TCM) or palliative treatment, and treatment efficacy (p<0.05) are factors influencing patient participation in MDT. Multivariate analysis shows that patients in North China (OR: 2.69, 95% CI: 1.98-3.67), Central China (OR: 1.59, 95% CI: 1.15-2.21), Southwest China (OR: 5.19, 95% CI: 3.78-7.11), and Northwest China (OR: 2.28, 95% CI: 1.51-3.43) are more likely to participate in MDT. Patients treated at city-level hospitals (OR: 1.84, 95% CI: 1.50-2.26) and those receiving care at two hospitals (OR: 1.28, 95% CI: 1.02-1.61) also show higher MDT participation rates. Those in the recurrent treatment phase (OR: 3.21, 95% CI: 1.56-6.58) are significantly more likely to engage in MDT. Additionally, patients undergoing chemotherapy (OR: 2.62, 95% CI: 1.75-3.93), targeted therapy (OR: 1.38, 95% CI: 1.10-1.73), or traditional Chinese medicine (TCM)/palliative treatment (OR: 1.76, 95% CI: 1.41-2.22) have an increased likelihood of MDT participation. There is a positive association between participation in MDT and the overall health-related quality of life (HRQOL) score in colorectal cancer patients. Conclusion: Different regions, healthcare organizations, patients' stage of treatment, modalities of treatment and quality of life influence access to MDT for patients with Stage IV CRC, while MDT care is significantly associated with better quality of life.